The RF model incorporating clinical and biological markers effectively predicts decline in treatment efficacy among PD patients, with fecal calprotectin, fecal lactoferrin, and the E. coli/Lactobacillus ratio serving as key predictors. Here, LTF is linked to Parkinson disease.